Related Experiment Video
Updated: Aug 24, 2025
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Bronchiolitis therapies and misadventures
Rosalie S N Linssen1, Michael S Schechter2, Bruce K Rubin2
1Amsterdam University Medical Center, Location AMC, Meibergdreef 9, 1105AZ Amsterdam, the Netherlands.
Insights
Respiratory syncytial virus (RSV) causes bronchiolitis in young children, with supportive care remaining the primary treatment. Future research should explore varied age groups and subgroups for effective bronchiolitis therapies.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pulmonology
Background:
- Bronchiolitis, primarily caused by respiratory syncytial virus (RSV), is a common respiratory illness in infants and young children.
- Current management for bronchiolitis relies exclusively on supportive care, lacking targeted antiviral or anti-inflammatory treatments.
- Despite extensive research, effective pharmacological interventions for bronchiolitis remain elusive.
Purpose of the Study:
- To review the historical progression of bronchiolitis treatments, including those that were unsuccessful.
- To examine novel and emerging therapies currently under investigation for managing bronchiolitis.
- To highlight the need for stratified approaches in future clinical trials.
Main Methods:
- Systematic review of published literature on bronchiolitis treatments.
- Analysis of historical treatment strategies and their outcomes.
- Evaluation of ongoing clinical trials for new bronchiolitis therapies.
Main Results:
- Many previously investigated treatments for bronchiolitis have proven ineffective.
- Several new therapeutic agents are in various stages of clinical development.
- Treatment responses may vary significantly across different pediatric subgroups.
Conclusions:
- Supportive care continues to be the cornerstone of bronchiolitis management.
- Future research must investigate treatments considering age, prior wheezing history, family asthma history, and non-RSV viral causes.
- Personalized treatment strategies are crucial for optimizing outcomes in pediatric bronchiolitis.
Abstract:
Viral bronchiolitis, which is most commonly caused by an infection with the respiratory syncytial virus (RSV), can lead to respiratory difficulties in young children which may require hospitalization. Despite years of research and medical trials, the mainstay of bronchiolitis treatment remains supportive only. This review provides an overview of the history of different treatments for bronchiolitis, including those that failed, as well as new therapies that are under study. Future studies for the treatment of bronchiolitis should consider different age-groups, important subgroups (i.e., those with a prior history of wheezing, those with a family history of asthma and those with non-RSV viral etiologies) whose response to treatment may differ from that of the composite group.
Related Concept Videos
01:17Pulmonary Cycle: Exhalation
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:29Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...